pharma · Alzheimer Disease · Pulmonary Fibrosis
Shanghai University of
Shanghai University of Traditional Chinese Medicine
Shanghai University of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Alzheimer Disease, Pulmonary Fibrosis, RESPIRATORY SYNCYTIAL VIRUS INFECTIONS, Chemotherapy, Adjuvant, Neoplasm
Shanghai, China, CN HQ
6 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Shanghai, China, CN
- Employees
- 6
- Programs
- 24
- Drugs
- 33
- Patents
- 0
JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)
Phase 1 · mab · Diffuse Large B Cell Lymphoma
JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells) for Diffuse Large B Cell Lymphoma is a Phase 1 program (mab) at Shanghai University of Traditional Chinese Medicine with 1 ClinicalTrials.gov record(s).
Internal code JWCAR029-003
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shanghai University of Traditional Chinese Medicine
- Phase
- Phase 1
- Modality
- mab
- Indication
- Diffuse Large B Cell Lymphoma
- Status
- completed
- Trials
- 1